logo

Bluebird Bio Inc. (BLUE)



Trade BLUE now with
  Date
  Headline
5/10/2022 4:44:33 PM Wedbush Is Raising bluebird bio Inc. (BLUE) FY22 Rev. Estimate To 4.1 M From 2.1 M
5/10/2022 4:44:10 PM Wedbush Is Lowering bluebird bio Inc. (BLUE) FY22 Estimate To -4.32 From -3.99
5/10/2022 4:43:49 PM Wedbush Is Lowering bluebird bio Inc. (BLUE) Q4 22 Estimate To -0.68 From -0.63
5/10/2022 4:43:29 PM Wedbush Is Lowering bluebird bio Inc. (BLUE) Q3 22 Estimate To -0.70 From -0.66
5/10/2022 4:43:15 PM Wedbush Is Lowering bluebird bio Inc. (BLUE) Q2 22 Estimate To -1.28 From -1.11
5/10/2022 4:42:53 PM Wedbush Reiterates bluebird bio Inc. (BLUE) At Neutral With $8 Down From $10 Price Target
4/5/2022 7:43:56 AM Bluebird Bio Initiates Restructuring; Plans To Reduce Its Workforce By About 30%
3/7/2022 8:23:47 AM Wedbush Is Raising bluebird bio Inc. (BLUE) FY22 Estimate To -4.51 From -4.96
3/7/2022 8:23:24 AM Wedbush Is Raising bluebird bio Inc. (BLUE) Q3 22 Estimate To -0.93 From -1.30
3/7/2022 8:23:11 AM Wedbush Is Raising bluebird bio Inc. (BLUE) Q2 22 Estimate To -0.99 From -1.38
3/7/2022 8:22:59 AM Wedbush Is Lowering bluebird bio Inc. (BLUE) Q1 22 Estimate To -1.68 From -1.38
3/7/2022 8:21:37 AM Wedbush Reiterates bluebird bio Inc. (BLUE) At Neutral With $10 Down From $11 Price Target
1/18/2022 7:05:22 AM Bluebird Bio : FDA Extends Review Period For BLA For Lentiviral Vector Gene Therapies
12/20/2021 8:09:44 AM Bluebird Bio Reports Partial Clinical Hold For Patients Under 18 In Sickle Cell Gene Therapy Clinical Program